This dataset provides a comprehensive technical and clinical overview of Spravato (Esketamine) 56mg Nasal Spray, the first FDA-approved nasal treatment for treatment-resistant depression (TRD). Each dose kit contains two 28mg single-use devices, delivering a pharmaceutical-grade formulation that targets the brain’s NMDA receptors to promote rapid synaptogenesis. This data is essential for researchers at NIASRA and the University of Wollongong (UOW) focused on interventional psychiatry and neuroplasticity.
Technical Specifications
• Active Ingredient: Esketamine (the S-enantiomer of ketamine)
• Concentration: 28mg per device (56mg total per Dose Kit)
• Mechanism: Non-competitive NMDA receptor antagonist
• Regulatory Status: FDA-Approved for TRD and suicidal ideation
• Delivery Method: Intranasal (Single-use devices)
Clinical & Research Applications
• Rapid Antidepressant Effects: Investigating symptom relief timelines, often observed within 24 hours of administration.
• Neuroplasticity & Synaptogenesis: Exploring the modulation of glutamate receptors to restore neural connections.
• Treatment-Resistant Depression (TRD): Analyzing efficacy in patients who have failed to respond to at least two different oral antidepressants.
• Co-Occurring Anxiety: Researching the secondary benefits of esketamine in reducing anxiety levels through neural pathway “resetting.”
Patient Experience & Safety Data
• Dissociative Effects: Documenting the temporary state of dissociation and sensory changes peaking at 40 minutes post-administration.
• Monitoring Protocols: Analyzing the importance of post-administration observation for blood pressure and sedation.
• Duration of Relief: Tracking the enduring antidepressant benefits versus the short-lived acute effects.
Source Information
For detailed clinical data and pharmaceutical-grade procurement, visit:
https://lyfeunit.com/product/spravato-esketamine-56mg-nasal-spray-dose-kit/